Belatacept

Belatacept
Clinical data
Trade names	Nulojix
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a606016
License data	EU EMA: by INN; US FDA: Belatacept;
Routes of; administration	Intravenous
ATC code	L04AA28 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only;
Identifiers
ChemSpider	none;
UNII	E3B2GI648A;
	(what is this?) (verify)

Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,^[2] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant^[3] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.^[4]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Vincenti, Flavio; Rostaing, Lionel; Grinyo, Joseph; Rice, Kim; Steinberg, Steven; Gaite, Luis; Moal, Marie-Christine; Mondragon-Ramirez, Guillermo A.; Kothari, Jatin; Polinsky, Martin S.; Meier-Kriesche, Herwig-Ulf; Munier, Stephane; Larsen, Christian P. (2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation | NEJM". New England Journal of Medicine. 374 (4): 333–343. doi:10.1056/NEJMoa1506027. PMID 26816011.
^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16. {{cite press release}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[urlctla4igenglish-2] "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[3] Vincenti, Flavio; Rostaing, Lionel; Grinyo, Joseph; Rice, Kim; Steinberg, Steven; Gaite, Luis; Moal, Marie-Christine; Mondragon-Ramirez, Guillermo A.; Kothari, Jatin; Polinsky, Martin S.; Meier-Kriesche, Herwig-Ulf; Munier, Stephane; Larsen, Christian P. (2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation | NEJM". New England Journal of Medicine. 374 (4): 333–343. doi:10.1056/NEJMoa1506027. PMID 26816011.

[4] "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16. {{cite press release}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[1]

[2]

[3]

[4]